The US Food and Drug Administration has granted final approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Citalopram Hydrobromide Tablets, 10 mg, 20 mg and 40 mg. Citalopram Hydrobromide is the generic version of Forest Laboratories Inc.'s Celexa.
Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.